Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCR | P30988 | 4/20 | 0.59 |
| ▸ | APLNR | P35414 | 2/20 | 0.59 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.56 |
| ▸ | F2 | P00734 | 4/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.54 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.54 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.54 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31296089 | 0.94 | APLNR (0.61) | CALCRAPLNRC5AR1F2MAPK8 | |
| SCHEMBL29679646 | 0.90 | F2 (0.61) | CALCRAPLNRF2 | |
| SCHEMBL29432915 | 0.90 | MAPK8 (0.54) | OPRM1OPRK1MAPK8MAPK9MAPK10 | |
| SCHEMBL31303836 | 0.89 | CALCR (0.64) | CALCRAPLNRC5AR1F2 | |
| SCHEMBL30495675 | 0.88 | CALCR (0.60) | CALCRAPLNRF2 | |
| SCHEMBL29597451 | 0.88 | CALCR (0.66) | CALCRF2 | |
| SCHEMBL30358178 | 0.88 | CALCR (0.66) | CALCR | |
| SCHEMBL29678024 | 0.87 | OPRM1 (0.58) | CALCRAPLNRC5AR1OPRM1OPRK1 | |
| SCHEMBL29822539 | 0.87 | F2 (0.62) | CALCRAPLNRF2MAPK8MAPK9 | |
| SCHEMBL29667180 | 0.87 | NPY2R (0.56) | CALCRAPLNRC5AR1MAPK8MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 237 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-20240358939-A1 | INTERNAL CANNULA MOUNTED NEBULIZER | VAPOTHERM, INC. | 2024-10-31 | — | — | US | claimed |
| EP-4034211-A1 | INTERNAL CANNULA MOUNTED NEBULIZER | Vapotherm, Inc. (US) | 2022-08-03 | — | — | EP | claimed |
| CN-114728147-A | Cannula internally mounted atomizer | 蒸汽热能公司 | 2022-07-08 | — | — | CN | claimed |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-05-12 | — | — | US | disclosed |
| US-12624343-B2 | Extracellular vesicles (EVs) derived from mesenchymal stromal cells and method for obtaining said EVs | EXO BIOLOGICS SA (BE) | 2026-05-12 | — | — | US | disclosed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | disclosed |
| US-12616695-B2 | Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of rare chronic inflammatory pulmonary diseases | METRIOPHARM AG (CH) | 2026-05-05 | — | — | US | disclosed |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-14 | — | — | US | disclosed |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-07 | — | — | US | disclosed |
| EP-3481958-B1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DISORDERS AND DISEASES INVOLVING RDH12 | UNIV PENNSYLVANIA (US) | 2026-04-01 | — | — | EP | disclosed |
| EP-3668319-B1 | PURIFIED MESENCHYMAL STEM CELL EXOSOMES AND USES THEREOF | CHILDRENS MEDICAL CENTER (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-3966223-A1 | PEPTIDOMIMETIC AGENTS, SYNTHESIS AND USES THEREOF | The Feinstein Institutes for Medical Research (US) | 2022-03-16 | — | — | EP | disclosed |
| EP-3966201-A1 | THIOSEMICARBAZATES AND USES THEREOF | The Feinstein Institutes for Medical Research (US) | 2022-03-16 | — | — | EP | disclosed |
| US-20220049275-A1 | SSI CELLS WITH PREDICTABLE AND STABLE TRANSGENE EXPRESSION AND METHODS OF FORMATION | LONZA AG (CH) | 2022-02-17 | — | — | US | disclosed |
| US-20220042064-A1 | CARBON-SOURCE REGULATED PROTEIN PRODUCTION IN A RECOMBINANT HOST CELL | LONZA LTD (CH) | 2022-02-10 | — | — | US | disclosed |
| EP-3947695-A1 | MUT- METHYLOTROPHIC YEAST | Universität für Bodenkultur Wien (AT) | 2022-02-09 | — | — | EP | disclosed |
| US-11236520-B2 | Customizable facility | LONZA LTD (CH) | 2022-02-01 | — | — | US | disclosed |
| US-20220023347-A9 | PURIFIED MESENCHYMAL STEM CELL EXOSOMES AND USES THEREOF | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2022-01-27 | — | — | US | disclosed |
| EP-3942014-A1 | CONTINUOUS BLADE IMPELLER | Lonza Ltd. (CH) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | GLUL, ARGLU1, ASNS | CALCR 2542/4885APLNR 354/4885C5AR1 1317/4885 |
| US-12624343-B2 | Extracellular vesicles (EVs) derived from mesenchymal stromal cells and method for obtaining said EVs | CD63, TFRC, EXOSC9 | CALCR 3300/4885APLNR 2047/4885C5AR1 1733/4885 |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | TST, THRB, HSPB1 | CALCR 1795/4885APLNR 947/4885C5AR1 2673/4885 |
| US-12616695-B2 | Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of rare chronic inflammatory pulmonary diseases | CRYZ, PDE12, FKBP5 | CALCR 4542/4885APLNR 4063/4885C5AR1 3784/4885 |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | MET, THRB, ABAT | CALCR 1581/4885APLNR 1687/4885C5AR1 1785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.